On October 28, 2024, the Breakthrough T1D Centre of Excellence at the University of British Columbia (UBC) held its third annual meeting on UBC campus in Vancouver to discuss progress to date as well as the team’s ambitious plans for Years 4 and 5 of the research program. During Year 3, the team made several […]
Breakthrough T1D’s largest advocacy event – Kids For a Cure was held from November 3rd to 5th in Ottawa, Ontario. Held every two years, Kids for a Cure is Breakthrough T1D Canada’s most important advocacy initiative. Our youth advocates from across Canada help politicians understand the daily challenges of living with type 1 diabetes (T1D) […]
Dr. Alyssa Weinrauch is the third annual recipient of the J. Andrew McKee Fellowship in Type 1 Diabetes (T1D), jointly funded by Breakthrough T1D Canada and the Stem Cell Network (SCN) based at the Breakthrough T1D Centre of Excellence at the University of British Columbia (UBC). The J. Andrew McKee Fellowship in Type 1 Diabetes, […]
Since 1986, corporate Canada has been participating in one of Canada’s longest running and top fundraising events, the JDRF Ride to Defeat Diabetes. This year rides were held in Montréal and Toronto on October 10 and 16 and 17, respectively, along with ‘Ride Your Way’ events taking place across the country all October. T1D is […]
From September 9-13th, 2024, scientists, healthcare professionals, and the diabetes community from around the world gathered in Madrid, Spain for the European Association for the Study of Diabetes (EASD) annual conference. The event was attended by researchers, clinicians, pharmaceutical and device companies, regulators and leaders in the diabetes field from more than 120 countries, and […]
JDRF Canada is pleased to share that our US affiliate Breakthrough T1D (formerly JDRF, headquartered in the US) has awarded an Industry Drug and Development Grant to Integrated Nanotherapeutics (“INT”, Vancouver, BC). Founded by academic scientists, including Dr. Bruce Verchere – lead of the JDRF Centre of Excellence at UBC – INT is a biotechnology […]
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer. Results from a clinical trial named USTEKID, published in the journal Nature Medicine, suggest that ustekinumab may be effective in treating the early stages of type 1 diabetes in children and […]
Meet Bonnie Barber from Regina, SK, a resilient mother of seven, valued JDRF donor, and longstanding volunteer leader helping to champion JDRF Canada’s $100M Campaign to Accelerate. Bonnie shares her journey navigating the challenging early moments of her two children’s type 1 diabetes (T1D) diagnoses, how this relentless disease has impacted her family, and what […]
“Alone we can do so little; together we can do so much.” – Helen Keller, Disability rights advocate Since our founding 50 years ago, JDRF Canada has helped fuel almost every advancement in type 1 diabetes (T1D) care and cure research by bringing together the T1D community, donors, researchers, and funding partners to work towards […]
The JDRF Canada Clinician Investigator Fellowship is open to medical residents that are pursuing an additional research degree (Master, PhD, or postdoctoral training) in the field of type 1 diabetes research. Residents must be part of their university’s Clinician Investigator Program (CIP) which is guided by The Royal College of Physicians and Surgeons of Canada. […]
Miguel Alvarez, who has been living with type 1 diabetes for over 55 years, aims to complete two bike rides of over 100 miles each. To mark his 55th ‘Diaversary’ – the date when someone was diagnosed with type 1 diabetes (T1D), Vancouver, BC resident Miguel Alvarez will be attempting two 100-mile bike rides: the […]
On Friday, March 28, 2025 news from Vertex came announcing that they are discontinuing one of their T1D cell therapy trials. VX-264 is the trial of stem cell-derived islet cells that are transplanted in a macroencapsulation device (like tea leaves in a teabag) without the need for immunosuppression. Unfortunately, although the first phase of the trial was […]
